Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug

Дата публикации: 07-04-2026 16:31:38

Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease Prader-Willi syndrome.Continue reading

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma	0	5	09-03-2026
2	Why Biogen Is Paying $5.6B to Buy Apellis Pharma	0	5	03-04-2026
3	STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk	0	9.8	13-08-2026
4	Novartis is buying a U.K. cancer drug startup for up to $1.5 billion	0	7	06-07-2026
5	Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis	0	5	08-04-2026
6	Skadden, Baker McKenzie Guide $7B Onsemi, Synaptics Deal	0	5	26-06-2026
7	Why Quantum Health Acquired Virtual Care Company CirrusMD	0	5	09-03-2026
8	Siddharth Mittal Appointed As Managing Director & CEO Of Syngene International	0	5	01-07-2026
9	Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1	0	13.47	11-08-2026
10	FDA Grants Accelerated Approval for Genglycos (pariglasgene brecaparvovec-opnr) Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia	0	13.83	19-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 7. Источник: dealbreaker.com.